Log in

Relevant bibliographies by topics / Pharmaceutical company / Journal articles

To see the other types of publications on this topic, follow the link: Pharmaceutical company.

Journal articles on the topic 'Pharmaceutical company'

Author: Grafiati

Published: 4 June 2021

Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pharmaceutical company.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Deuskar, Vishwa. "Comparative Profitability Analysis: Sun Pharmaceutical Company & Cipla Pharmaceutical Company." RESEARCH REVIEW International Journal of Multidisciplinary 7, no. 8 (2022): 109–14. http://dx.doi.org/10.31305/rrijm.2022.v07.i08.017.

Full text

Abstract:

The Indian pharmaceutical industry is growing tremendously. Indian pharmaceutical industry plays a prominent role in the global pharmaceutical industry. It contributes to the welfare of people and provides significant socio-economic benefits to the society through creation of jobs, supply chains and community development. This study has been done for important evaluation of two Indian giant pharmaceutical industries i.e. Sun pharmaceutical Ltd. and Cipla pharmaceuticals. This study focuses on to analyze the profitability of the selected pharmaceutical companies of India and to do comparative s

APA, Harvard, Vancouver, ISO, and other styles

2

Sadler, John Z. "Pharmaceutical Company Influence." Hastings Center Report 41, no. 2 (2011): S22. http://dx.doi.org/10.1353/hcr.2011.0054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Erle, Henry R. "A modern pharmaceutical company." Clinical Pharmacology [amp ] Therapeutics 71, no. 1 (2002): 103. http://dx.doi.org/10.1067/mcp.2002.120165.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

SHAPIRO, J. D., K.-A. PHILLIPS, and I. F. TANNOCK. "More pharmaceutical company influence?" Australian and New Zealand Journal of Medicine 28, no. 5 (1998): 675. http://dx.doi.org/10.1111/j.1445-5994.1998.tb00676.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Saravanan, Dr S., and R. Prabhu. "A Study on Financial Performance of Pharmaceutical Company." International Journal of Trend in Scientific Research and Development Volume-2, Issue-3 (2018): 1904–7. http://dx.doi.org/10.31142/ijtsrd11425.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Shantanu R. Kulkarni. "Implementation of Track and Trace Systems at Pharmaceuticals Industry Ltd." Journal of Information Systems Engineering and Management 10, no. 19s (2025): 834–41. https://doi.org/10.52783/jisem.v10i19s.3120.

Full text

Abstract:

The pharmaceutical industry faces significant challenges in ensuring its products' safety, authenticity, and regulatory compliance. global pharmaceutical company has implemented advanced Track and Trace (T&T) systems to enhance supply chain visibility, combat counterfeiting, and ensure patient safety. This journal explores the key strategies, technological frameworks, and benefits of implementing T&T systems at global pharmaceuticals company. The paper also examines the regulatory landscape influencing T&T adoption and the challenges encountered during implementation.

APA, Harvard, Vancouver, ISO, and other styles

7

Kwon, Ki-Hwan, Ga-Yeon Kim, Ju-Hee Oh, Hye-Min Lee, Yeon-Jin Lim, and Mun-Hyeon Jeong. "CELLTRION: Towards Global Pharmaceutical Company." Korea Business Review 25, no. 2 (2021): 1–32. http://dx.doi.org/10.17287/kbr.2021.25.2.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Rosenblatt, Michael. "The Large Pharmaceutical Company Perspective." New England Journal of Medicine 376, no. 1 (2017): 52–60. http://dx.doi.org/10.1056/nejmra1510069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Schulte, Lorraine. "A New Pharmaceutical Company Library." Science & Technology Libraries 7, no. 1 (1986): 15–30. http://dx.doi.org/10.1300/j122v07n01_03.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Sykes, R. "Being a modern pharmaceutical company." BMJ 317, no. 7167 (1998): 1172–80. http://dx.doi.org/10.1136/bmj.317.7167.1172.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Ross, Joseph S., Josh E. Lackner, Peter Lurie, Cary P. Gross, Sidney Wolfe, and Harlan M. Krumholz. "Pharmaceutical Company Payments to Physicians." JAMA 297, no. 11 (2007): 1216. http://dx.doi.org/10.1001/jama.297.11.1216.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Garcia, Antonio, Hector M. Rivas, Jorge L. Figueroa, and Alex L. Monroe. "Case history: Pharmaceutical wastewater treatment plant upgrade, SmithKline Beecham Pharmaceuticals Company." Desalination 102, no. 1-3 (1995): 255–63. http://dx.doi.org/10.1016/0011-9164(95)00061-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Bensadok, Esmeralda, and Nabila Abid. "Organisational Resilience as a Business Strategic Imperative in Times of Crisis: Case of Hikma Pharma Algeria." Business Ethics and Leadership 7, no. 4 (2023): 24–36. http://dx.doi.org/10.61093/bel.7(4).24-36.2023.

Full text

Abstract:

In light of the COVID-19 health crisis, organisational resilience appears more than ever to be a necessity, a strategic imperative for companies during this unprecedented crisis. Companies that were able to adapt their business model to the particular circumstances created by the COVID crisis are those that were able to adjust quickly to deal with the emergency by developing new working practices or by responding flexibly to customer needs. Thus, organisational resilience refers to the ability of organisations to resist and overcome crises by developing resilience mechanisms that enable them t

APA, Harvard, Vancouver, ISO, and other styles

14

Aprilia, Lidiya, and Dwi Urip Wardoyo. "Pengaruh Manajemen Risiko, Intellectual Capital, Profitabilitas dan Ukuran Perusahaan Terhadap Nilai Perusahaan." Owner 8, no. 1 (2024): 276–83. http://dx.doi.org/10.33395/owner.v8i1.1841.

Full text

Abstract:

Firm value is an investor's view of the company as seen through the stock price, the higher the stock price, it will indicate that the company has a high corporate value. That’s urgents of pharmaceuticals company to maintain company value. On the other hand, company value attracts potential investors to invest and increase public confidence in using the company's products. Finding effect of risk management, intellectual capital, profitability and company size on firm value in pharmaceutical sub-sector companies listed on the IDX Industry Classification for 2018 – 2022. This research uses quant

APA, Harvard, Vancouver, ISO, and other styles

15

Rochman, Didit Damur, and Annisa Maharani. "PRIORITAS KAPABILITAS DINAMIS VS OPERASIONAL ATAS KINERJA PERUSAHAAN DENGAN GREY-AHP." Jurnal Lebesgue : Jurnal Ilmiah Pendidikan Matematika, Matematika dan Statistika 5, no. 1 (2024): 441–51. http://dx.doi.org/10.46306/lb.v5i1.580.

Full text

Abstract:

The operational capabilities of a company represent its routine and ordinary activities undertaken to sustain and generate performance. In the manufacturing sector, particularly in pharmaceuticals, there is a greater demand for higher operational capabilities compared to other manufacturing sectors due to the relevance to human health. The pivotal role of dynamic capabilities is purported to significantly impact the enhancement of operational capabilities, both directly and indirectly affecting company performance. This research proposal aims to investigate how dynamic capabilities influence c

APA, Harvard, Vancouver, ISO, and other styles

16

Qi, Lin, and Xinrong Zeng. "Financial Performance Analysis under the Light Asset Operation Model of Tai Long Pharmaceutical Company." Frontiers in Business, Economics and Management 17, no. 1 (2024): 200–207. http://dx.doi.org/10.54097/5jfzy084.

Full text

Abstract:

With the rapid development of the pharmaceutical industry and the increasingly fierce competition, the light asset operation model has become a key strategic choice for transforming pharmaceutical companies. This paper takes Tai Long Pharmaceutical as a case study to analyze its CXO light asset operation model and financial characteristics in depth. By employing factor analysis, a comprehensive assessment of its economic performance is conducted, and suggestions aimed at enhancing Tai Long Pharmaceutical's financial performance are proposed based on the analysis results, to help the company ma

APA, Harvard, Vancouver, ISO, and other styles

17

Xue, Guanglu. "Analysis of Kangmei Pharmaceutical’s Financial Restatement Behavior from the Perspective of Corporate Governance." E3S Web of Conferences 218 (2020): 02016. http://dx.doi.org/10.1051/e3sconf/202021802016.

Full text

Abstract:

The object is Kangmei Pharmaceutical, a listed company in the pharmaceutical sector. The research is based on corporate governance, the company’s financial restatement behavior is analyzed based on the four aspects of Kangmei Pharmaceutical’s equity structure, institutional investors, independent audit institutions, media and regulatory agencies. In order to avoid Kangmei Pharmaceutical’s adjustments, several countermeasures and suggestions are put forward, and improve the corporate governance theory of the capital market.

APA, Harvard, Vancouver, ISO, and other styles

18

Chilunjika, Sharon R. T., Alouis Chilunjika, and Dominique E. Uwizeyimana. "Implementing e-procurement at the Zimbabwe’s National Pharmaceutical Company (NatPharm): Challenges and Prospects." JeDEM - eJournal of eDemocracy and Open Government 15, no. 1 (2023): 124–43. http://dx.doi.org/10.29379/jedem.v15i1.761.

Full text

Abstract:

This study explores the challenges and benefits of adopting electronic procurement (e-procurement) technologies to facilitate anti-corruption mechanisms, accountability and transparency in the procurement of pharmaceuticals at the National Pharmaceutical (NatPharm) Company in Zimbabwe. Pharmaceutical corruption is a serious threat to the attainment of Universal Health Coverage. It is imperative for the Government of Zimbabwe to adopt Information Communication Technologies (ICTs) to detect and prevent corruption and fraud, thereby, addressing leakages, mismanagement and theft of medicines, ther

APA, Harvard, Vancouver, ISO, and other styles

19

Clemow, D. B., C. Sapin, T. Hibi, et al. "A186 ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION." Journal of the Canadian Association of Gastroenterology 6, Supplement_1 (2023): 31–32. http://dx.doi.org/10.1093/jcag/gwac036.186.

Full text

Abstract:

Abstract Background Ulcerative colitis (UC) can result in a high prevalence of bowel movement urgency (BU), significantly reducing patient quality of life. Purpose Early BU improvement association with later clinical endpoint improvements was examined in moderately-to-severely active UC patients (pts) treated with mirikizumab (miri). Method BU was evaluated in Phase 3 randomized placebo (PBO)-controlled 12-week induction (LUCENT-1, NCT03518086) and 40-week maintenance (LUCENT-2, NCT03524092) trials with miri. Pts received IV miri 300mg or PBO during induction. Week (W)12 miri responders were r

APA, Harvard, Vancouver, ISO, and other styles

20

Hossain, Niamat Ullah Ibne, Farjana Nur, and Md Ahasan Habib. "ACHIEVING COMPETITIVE ADVANTAGE THROUGH PRACTICING TQM TOOLS IN PHARMACEUTICALS COMPANY." Journal of Mechanical Engineering 43, no. 2 (2014): 103–9. http://dx.doi.org/10.3329/jme.v43i2.17834.

Full text

Abstract:

In order to survive in a competitive market, improving quality and productivity of Product or processis a must for any company. And in case of pharmaceutical industry, effective quality assurance policyimplementation is the most important goal. The main objective of this paper is to apply the Total QualityManagement (TQM) tools in a pharmaceutical company and prove its advantage. Here Control Chart,Fishbone diagram, EWMA were used and the control limits were improved. This activity resulted in moreperfect control limit recommendations which actually capable of reducing the material cost. The T

APA, Harvard, Vancouver, ISO, and other styles

21

Novak, Kristine. "Angiogenesis team sued by pharmaceutical company." Nature Medicine 6, no. 7 (2000): 723. http://dx.doi.org/10.1038/77414.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Lane, Stuart M. "Establishing guidelines on pharmaceutical company support." American Journal of Health-System Pharmacy 49, no. 5 (1992): 1108–9. http://dx.doi.org/10.1093/ajhp/49.5.1108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Spurling, Geoffrey, Peter Mansfield, and Joel Lexchin. "Pharmaceutical company advertising in The Lancet." Lancet 378, no. 9785 (2011): 30. http://dx.doi.org/10.1016/s0140-6736(11)61019-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Visser, BJ. "Networking request from a pharmaceutical company?" Lancet 378, no. 9799 (2011): 1295–96. http://dx.doi.org/10.1016/s0140-6736(11)61573-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

DAY, R. "Pharmaceutical company promotion: striking a balance." Australian and New Zealand Journal of Medicine 28, no. 3 (1998): 291–93. http://dx.doi.org/10.1111/j.1445-5994.1998.tb01950.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Goldstein, A. O. "Pharmacoeconomic considerations in pharmaceutical company promotions." Archives of Family Medicine 3, no. 12 (1994): 1034–35. http://dx.doi.org/10.1001/archfami.3.12.1034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Rosenberg, G. B. "Pharmacoeconomic considerations in pharmaceutical company promotions." Archives of Family Medicine 4, no. 8 (1995): 674b—675. http://dx.doi.org/10.1001/archfami.4.8.674b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Levy, Moshe Yair, Lin Xie, Yuexi Wang, et al. "Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib." Blood 134, Supplement_1 (2019): 4751. http://dx.doi.org/10.1182/blood-2019-129053.

Full text

Abstract:

INTRODUCTION: Chronic myeloid leukemia (CML) is a bone marrow and blood disorder accounting for 15% of adult leukemia. Tyrosine kinase inhibitors (TKIs) have been the standard of care for CML treatment. However, an association between TKI use and cardiovascular events has been observed. Ponatinib and bosutinib are introduced to provide more options for patients who failed their first-line treatment. The incidence of major adverse cardiac events (MACEs), arterial occlusive events (AOEs), and venous occlusive events (VOEs) were assessed among CML patients who were prescribed ponatinib vs bosutin

APA, Harvard, Vancouver, ISO, and other styles

29

Hemphill, Thomas A., and Scott D. Johnson. "Premium-Priced, Branded Generic Pharmaceuticals in Emerging Economies." Business and Professional Ethics Journal 39, no. 3 (2020): 287–317. http://dx.doi.org/10.5840/bpej202091099.

Full text

Abstract:

Is it socially responsible to price at a premium, company branded generic pharmaceuticals in emerging economies? Building toward an answer to this question, the study first describes the role of the branded generic sector in the economic success of the global pharmaceutical industry. Second, the concept of “shared value,” i.e., the link between competitive advantage (and its theoretical antecedents found in corporate reputation and signaling theory) and corporate social responsibility (CSR), is introduced and applied to the global pharmaceutical industry’s position on marketing generic pharmac

APA, Harvard, Vancouver, ISO, and other styles

30

Jaafar, Kamal, and Jawahitha Sarabdeen. "XL Pharmaceutical – effective operation and logistics." Emerald Emerging Markets Case Studies 1, no. 4 (2011): 1–9. http://dx.doi.org/10.1108/20450621111194094.

Full text

Abstract:

TitleXL Pharmaceutical – effective operation and logistics.Subject areaOperation and logistics.Study level/applicabilityStudents and practitioners.Case overviewThis case study analysis the logistical and operational issues that one of the leading pharmaceutical companies in the MENA region is facing. The case provides a practical example of a company which positioned itself well to be a leading company. However, there are some inherent operational and logistical problems that hinder the company to reach its leading position. The first section of this case describes the company, its process and

APA, Harvard, Vancouver, ISO, and other styles

31

Kumar, Shaji K., Robert F. Cornell, Ola Landgren, et al. "A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)." Blood 134, Supplement_1 (2019): 1867. http://dx.doi.org/10.1182/blood-2019-125629.

Full text

Abstract:

Background CD38 is highly expressed on MM cells, hence anti-CD38 agents are of interest as a therapeutic approach in MM. The anti-CD38 monoclonal antibody, dara, as mono- or combination therapy, has substantially improved efficacy outcomes in RRMM, including in heavily pretreated pts. However, many pts relapse and new therapeutic approaches are needed, particularly for pts R/R to dara. TAK-169 is a dimeric fusion protein of an anti-CD38 antibody single chain variable fragment fused to a modified Shiga-like toxin-A subunit. Its unique mechanism of action involves specific binding to CD38+ cells

APA, Harvard, Vancouver, ISO, and other styles

32

Dignass, A., S. Danese, K. Matsuoka, et al. "A185 SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL." Journal of the Canadian Association of Gastroenterology 6, Supplement_1 (2023): 29–31. http://dx.doi.org/10.1093/jcag/gwac036.185.

Full text

Abstract:

Abstract Background Mirikizumab (miri) improved symptom control in a Phase 3, multicenter, randomized, double-blind, parallel, placebo-controlled induction study at Week (W)12, in patients (pts) with moderately-to-severely active ulcerative colitis (UC; LUCENT-1). Purpose This analysis assessed sustained symptom control during the maintenance phase through W40 (W52 of continuous therapy), among pts who were induced into clinical response with miri. Method During the 40W maintenance study (LUCENT-2), pts (N=544) who achieved clinical response to miri 300mg Q4W by W12 of induction, were re-rando

APA, Harvard, Vancouver, ISO, and other styles

33

Danese, S., A. Dignass, K. Matsuoka, et al. "A184 EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL." Journal of the Canadian Association of Gastroenterology 6, Supplement_1 (2023): 28–29. http://dx.doi.org/10.1093/jcag/gwac036.184.

Full text

Abstract:

Abstract Background Mirikizumab (miri), an anti-IL23/p19 monoclonal antibody, demonstrated efficacy compared with placebo (PBO) in the Phase 3, multicentre, randomized, double-blind LUCENT-1 induction study in patients with moderately to severely active ulcerative colitis (UC, NCT03518086). Purpose This analysis assessed early onset of symptomatic improvement and symptomatic control during induction. Method During the 12-week (W) induction study, 1162 adult patients (pts) with inadequate response, loss of response, or were intolerant to conventional therapy or biologic or tofacitinib therapy f

APA, Harvard, Vancouver, ISO, and other styles

34

Hassan, F. "Being a modern pharmaceutical company: New paradigms for the pharmaceutical industry." Clinical Pharmacology & Therapeutics 69, no. 5 (2001): 281–85. http://dx.doi.org/10.1067/mcp.2001.115450.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Yoroidaka, Takeshi, Hiroyuki Takamatsu, Takeshi Yamashita, et al. "Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)." Blood 134, Supplement_1 (2019): 3130. http://dx.doi.org/10.1182/blood-2019-126552.

Full text

Abstract:

Background: Owing to the development of novel agents, the rate of complete response (CR) in multiple myeloma (MM) has increased. Additionally, the development of methods for measuring minimal residual disease (MRD) (e.g., multiparameter flow cytometry [MFC] and next-generation sequencing) has enabled us to stratify CR patients according to MRD levels. In this study, we hypothesized that deep response predicts better prognosis in MM. To investigate this hypothesis, we assessed the response of patients treated with carfilzomib + lenalidomide + dexamethasone (KRD) using MFC and compared survival

APA, Harvard, Vancouver, ISO, and other styles

36

Bekzhanova, Saule, Aliya Toktamysova, and Assel Alik. "RACKING EQUIPMENT DESIGN OF «VIVAPHARM» PHARMACEUTICAL COMPANY." Вестник КазАТК 119, no. 4 (2021): 23–34. http://dx.doi.org/10.52167/1609-1817-2021-119-4-23-34.

Full text

Abstract:

In this article, the authors substantiate the relevance of the development of a planning solution, which makes it possible to organize the storage of the largest amount of goods in the warehouse, taking into account the existing restrictions. Intelligently arranged shelving allows you to create additional space and optimize free space in the warehouse. By using the appropriate type of shelving, you can avoid unnecessary costs for additional premises, for manual labor, as well as reduce the time for solving other warehouse tasks. For the rational organization of the warehouse space of the "VIVA

APA, Harvard, Vancouver, ISO, and other styles

37

Choo, Youn Sung. "New Drug Development in Korean Pharmaceutical Company." Journal of the Korean Medical Association 46, no. 7 (2003): 562. http://dx.doi.org/10.5124/jkma.2003.46.7.562.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Strijbosch, L. W. G., R. M. J. Heuts, and M. L. J. Luijten. "Cyclical packaging planning at a pharmaceutical company." International Journal of Operations & Production Management 22, no. 5 (2002): 549–64. http://dx.doi.org/10.1108/01443570210425174.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Venables, K. M., R. D. Tee, E. R. Hawkins, et al. "Laboratory animal allergy in a pharmaceutical company." Occupational and Environmental Medicine 45, no. 10 (1988): 660–66. http://dx.doi.org/10.1136/oem.45.10.660.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Sones, Morgan, Susan Grantham, and Edward T. Vieira. "Communicating CSR via pharmaceutical company web sites." Corporate Communications: An International Journal 14, no. 2 (2009): 144–57. http://dx.doi.org/10.1108/13563280910953834.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Alexander-Banys, Bambi. "Pharmaceutical company advertising practices: Call to arms." Journal of Pediatric Health Care 16, no. 2 (2002): 49–50. http://dx.doi.org/10.1067/mph.2002.121543.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

ALEXANDERBANYS, B. "Pharmaceutical company advertising practices: Call to arms." Journal of Pediatric Health Care 16, no. 2 (2002): 49–50. http://dx.doi.org/10.1016/s0891-5245(02)96294-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Musher, Daniel M. "Pharmaceutical company- sponsored symposia and medical ethics." American Journal of Medicine 85, no. 4 (1988): 596. http://dx.doi.org/10.1016/s0002-9343(88)80123-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

AULT, ALICIA. "FDA: Pharmaceutical Company Receives ‘Bad Ad’ Warning." Skin & Allergy News 42, no. 1 (2011): 12. http://dx.doi.org/10.1016/s0037-6337(11)70011-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Chang, Chih-Wu, John G. Caster, Jed C. Morris, Roger P. Nelson, and David L. Larson. "Automated Information Delivery in a Pharmaceutical Company." Drug Information Journal 25, no. 1 (1991): 55–61. http://dx.doi.org/10.1177/009286159102500107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Freestone, D. S. "Reflections on Pharmaceutical Company Project Portfolio Management." Drug Information Journal 28, no. 3 (1994): 641–46. http://dx.doi.org/10.1177/009286159402800302.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Rogachev, Andrey Y. "Enterprise Risk Management In a Pharmaceutical Company." Risk Management 10, no. 1 (2008): 76–84. http://dx.doi.org/10.1057/palgrave.rm.8250037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Banerjee, Ashok. "Real Option Valuation of a Pharmaceutical Company." Vikalpa: The Journal for Decision Makers 28, no. 2 (2003): 61–73. http://dx.doi.org/10.1177/0256090920030205.

Full text

Abstract:

Valuing a research-driven firm is a challenging task. The static discounted cash flow (DCF) model fails to capture the value of R&D options. Pharmaceutical companies are, by their very nature, dependent on research products. These companies face an uncertain business environment. Roughly, one out of 10,000 explored chemicals becomes a prescription drug and only 30 per cent of drugs succeed in recovering their costs. Since the future of current R&D investments is uncertain, the traditional cash flow method may return a negative value of the future growth plan. Various studies have shown

APA, Harvard, Vancouver, ISO, and other styles

49

Bowman, M. A. "Pharmaceutical company/physician interactions. Finding the balance." Archives of Family Medicine 3, no. 4 (1994): 317–18. http://dx.doi.org/10.1001/archfami.3.4.317.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Di Bacco, Alessandra, Nizar J. Bahlis, Nikhil C. Munshi, et al. "Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)." Blood 128, no. 22 (2016): 243. http://dx.doi.org/10.1182/blood.v128.22.243.243.

Full text

Abstract:

Abstract Background Ixazomib, the first oral proteasome inhibitor, is approved by the US FDA, in combination with Rd, for the treatment of MM patients (pts) who have received at least 1 prior therapy. Approval was based on the double-blind, placebo-controlled phase 3 TOURMALINE-MM1 study (NCT01564537) in 722 pts with RRMM (Moreau et al, N Engl J Med 2016), in which IRd showed superior PFS versus placebo-Rd (HR 0.74) at the final prespecified analysis, with limited additional toxicity. Prespecified subgroup analyses showed a consistent PFS benefit with IRd, but with a differential treatment eff

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!